We now report that brensocatib downregulates the activity of the main pathophysiologically relevant DPP-1 substrates (e.g. NE, CatG, PR3) in two animal models of RA, and describe the outcomes of brensocatib treatment in these disease models. This evidence concerns the gene PRTN3 and rheumatoid arthritis.